BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 8230514)

  • 1. Experience with triple-drug therapy in a pharmacological erection program.
    Govier FE; McClure RD; Weissman RM; Gibbons RP; Pritchett TR; Kramer-Levien D
    J Urol; 1993 Dec; 150(6):1822-4. PubMed ID: 8230514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections.
    Meinhardt W; Lycklama à Nijeholt AA; Kropman RF; Vermeij P; Zwartendijk J
    Eur Urol; 1994; 26(4):319-21. PubMed ID: 7713130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.
    Lee LM; Stevenson RW; Szasz G
    J Urol; 1989 Mar; 141(3):549-50. PubMed ID: 2918589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.
    von Heyden B; Donatucci CF; Kaula N; Lue TF
    J Urol; 1993 May; 149(5 Pt 2):1288-90. PubMed ID: 8479018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
    Vardi Y; Lidgi S; Moskovitz B; Levin RD
    Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.
    Shenfeld O; Hanani J; Shalhav A; Vardi Y; Goldwasser B
    J Urol; 1995 Sep; 154(3):1017-9. PubMed ID: 7637045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracavernous self-injection pharmacotherapy program: analysis of results and complications.
    Valdevenito R; Melman A
    Int J Impot Res; 1994 Jun; 6(2):81-91. PubMed ID: 7951702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drop-out reasons and complications in self-injection therapy with a triple vasoactive drug mixture in sexual erectile dysfunction.
    Casabé A; Bechara A; Cheliz G; Romano S; Rey H; Fredotovich N
    Int J Impot Res; 1998 Mar; 10(1):5-9. PubMed ID: 9542684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
    Purvis K; Brekke I; Christiansen E
    Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of prolonged or priapistic erections following intracavernosal papaverine therapy.
    Padma-Nathan H; Goldstein I; Krane RJ
    Semin Urol; 1986 Nov; 4(4):236-8. PubMed ID: 3797893
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacological erection: diagnosis and treatment applications in 69 patients.
    Nellans RE; Ellis LR; Kramer-Levien D
    J Urol; 1987 Jul; 138(1):52-4. PubMed ID: 2439712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone.
    Floth A; Schramek P
    J Urol; 1991 Jan; 145(1):56-9. PubMed ID: 1984099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
    Asuar Aydillo S
    Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
    [No Abstract]   [Full Text] [Related]  

  • 16. [Prostaglandin E1 in erectile dysfunction].
    Porst H
    Urologe A; 1989 Mar; 28(2):94-8. PubMed ID: 2655258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with intracavernosal tri-mixture for the management of neurogenic erectile dysfunction.
    Chao R; Clowers DE
    Arch Phys Med Rehabil; 1994 Mar; 75(3):276-8. PubMed ID: 8129578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [3 years' experience with intracavernous auto-injection therapy].
    Weiske WH
    Urologe A; 1989 Sep; 28(5):253-6. PubMed ID: 2815435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An improved vasoactive drug combination for a pharmacological erection program.
    Bennett AH; Carpenter AJ; Barada JH
    J Urol; 1991 Dec; 146(6):1564-5. PubMed ID: 1719248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1.
    Allen RP; Engel RM; Smolev JK; Brendler CB
    J Urol; 1992 Oct; 148(4):1181-3. PubMed ID: 1404632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.